Skip to main content
Evidence Snapshot

Farnesyl pyrophosphate synthase

CHEMBL1782 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T01:05:24Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1782
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Farnesyl pyrophosphate synthase as ChEMBL target CHEMBL1782, mapped to UniProt P14324. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Farnesyl pyrophosphate synthase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1782
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P14324
Farnesyl pyrophosphate synthase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Farnesyl pyrophosphate synthase matters

As of 2026-09-13

Farnesyl pyrophosphate synthase is reviewed as Farnesyl pyrophosphate synthase (UniProt P14324); Farnesyl pyrophosphate synthase shows approved-linked disease relevance led by osteoporosis. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 13 approved drugs, 555 compounds, and 182 assays, with lead potency reaching pChEMBL 10.2.

Disease context
osteoporosis

Farnesyl pyrophosphate synthase shows approved-linked disease relevance led by osteoporosis. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALENDRONATE SODIUM, IBANDRONATE SODIUM, MINODRONIC ACID.

Start review with osteoporosis because it currently carries approved-linked support. Linked drugs include ALENDRONATE SODIUM, IBANDRONATE SODIUM, MINODRONIC ACID, RISEDRONATE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 5 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 13 approved drugs, 555 compounds, and 182 assays for this target. The dominant activity type is IC50. CHEMBL4303669 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL4303669 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
13 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Farnesyl pyrophosphate synthase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P14324, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why osteoporosis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

555
Total Compounds
182
Total Assays
13
Approved Drugs
IC50: 742.0, KI: 128.0, KD: 11.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4303669
 10.2 Ki Approved
No preferred name
CHEMBL4303669
 9.6 IC50 Approved
No preferred name
CHEMBL923
 9.4 IC50 Approved
No preferred name
CHEMBL923
 9.4 Ki Approved
No preferred name
CHEMBL100827
 9.2 IC50 —

Approved Drugs

Structure Compound First Approval
MINODRONIC ACID
CHEMBL319144
 2009
ZOLEDRONIC ACID
CHEMBL4303669
 2001
ZOLEDRONIC ACID ANHYDROUS
CHEMBL924
 2001
RISEDRONIC ACID
CHEMBL923
 1998
IBANDRONIC ACID
CHEMBL997
 1996
ALENDRONIC ACID
CHEMBL870
 1995
ALENDRONATE SODIUM
CHEMBL675
 1995
PAMIDRONIC ACID
CHEMBL834
 1991
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T01:05:24Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1782